#BoehringerIngelheim and #ClickTherapeutics have revealed the data from their pivotal trial of #digitaltherapeutic (DTx) CT-155 for #schizophrenia, which has shown efficacy against some of the symptoms that are hardest to address with drug therapies.

pharmaphorum.com/news/boehrin...

Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app

#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD

#ClickTherapeutics and #BoehringerIngelheim make progress in software-enhanced drug treatment for #schizophrenia with a positive phase 3 trial of their CT-155 app.

pharmaphorum.com/news/click-b...

FDA approves Click’s digital therapeutic for episodic migraine - PharmaTimes More than 37 million adults in the US are affected by migraine

#ClickTherapeutics #digitaltherapeutics #softwareenhanceddrugs #episodicmigraine #migraine #CT132 #preventionofepisodicmigraine #migraineprevention #migrainepatients #ReMMiDclincialtrial #migrainedays #ReMMiDCbridgingstudy #calcitoningenerelatedpeptideinhibitors
pharmatimes.com/news/fda-app...

FDA clears first migraine DTx from Click Therapeutics Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

NEWS: #ClickTherapeutics' digital therapeutic (#DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic #migraine.